“Sweat equity takes on a whole new meaning when you’re networking in a hot room,” says Chad Messer, a managing director at US ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, varegacestat for desmoid tumors, is not an ...

"We believe the timing of the deal reflects Amgen's confidence in the program," Needham's Chad Messer says of yesterday's strategic collaboration ...

Enthusiasts say high-temperature sessions sharpen focus, improve health, and offer a chance to build contacts. It’s a far cry ...